AbbVie Ups The Ante For Upadacitinib At EULAR

With data showing the superiority of its JAK inhibitor over Humira, the US firm is looking beyond treating the symptoms of rheumatoid arthritis to achieving remission.

EULAR
• Source: EULAR

With approvals for upadacitinib expected in the coming months, AbbVie Inc. has been making the case for its closely watched JAK1 inhibitor with long-term data demonstrating that the drug works better than its own mega-blockbuster Humira in keeping rheumatoid arthritis patients in clinical remission as well as improving their symptoms.

The US major presented new results from the SELECT-EARLY and SELECT-COMPARE Phase III trials at the European League Against Rheumatism...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category